We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.27% | 39.90 | 40.005 | 39.49 | 39.97 | 4,916,481 | 22:16:55 |
From Jul 2019 to Jul 2024
By Cecilia Butini
GlaxoSmithKline PLC said Thursday that it has kicked off a trial as part of its Phase 3 clinical program to test a treatment for severe eosinophilic asthma.
The trial, named SWIFT-2, is for an investigational medicine called GSK'294, a monoclonal antibody which is meant to suppress the protein responsible for the spread of eosinophils, a type of white blood cell involved in severe asthma.
The medicine is delivered as a subcutaneous injection every six months, GSK said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 18, 2021 06:08 ET (10:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
